Alivus Life Sciences Q4 FY26 EBITDA Margin Hits 34.4%

Alivus Life Sciences reported Q4 FY26 revenue of INR689 crore, up 6.1% YoY, with EBITDA margin expanding 230 bps to 34.4%.
Full-year FY26 revenue grew 6.9% to INR2,552 crore with EBITDA margin reaching 33.6%, the highest in company history.
The company plans INR540 crore capex for FY27, fully funded internally, focusing on Solapur expansion and R&D capabilities.
Non-GPL business contribution increased to 71% of revenue in FY26, reducing dependence on Glenmark Pharmaceuticals business.